RenovoRx

#Pancreatic Cancer #Locally Advanced Solid Tumors #Targeted Drug Delivery (TAMP therapy)

RenovoRx is a clinical-stage life-sciences company developing targeted oncology combination therapies, anchored by RenovoCath, a novel FDA-cleared local drug-delivery catheter for cancer treatment, and the TIGERPAC pivotal trial evaluating RenovoCath-delivered gemcitabine in locally advanced pancreatic cancer. The company reported record revenue (+115% year-over-year) and full enrollment in the pivotal TIGERPAC trial in its Q2 2026 results, regained Nasdaq minimum-bid-price compliance in August 2026, and holds a new U.S. patent allowance covering the RenovoCath dual-occlusion technology.

Company Info

Sector:Biotechnology / Oncology Drug Delivery (Medical Device)

Headquarters:Mountain View, California, USA

Founded:2012

Website:www.renovorx.com/

Upcoming Milestones & Key Dates

Aug 21, 2026

Regulatory / Compliance

Regained compliance with Nasdaq minimum bid price requirement

Aug 20, 2026

Regulatory / IP

Received U.S. notice of allowance for patent covering RenovoCath

Clinical Development Pipeline

RenovoCath (TIGERPAC trial)

Target: Intra-arterial gemcitabine delivered via RenovoCath dual-occlusion catheter (TAMP therapy)

Locally advanced pancreatic cancer

Preclinical

Phase 1

Phase 2

Phase 3

Approved

RenovoCath

Target: FDA-cleared dual-occlusion local drug-delivery catheter

Targeted therapeutic drug delivery for cancer treatment

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Recent News

No recent news updates available for this company.

Leadership Team

Shaun R. Bagai

Chief Executive Officer, Secretary and Director

Dr. Ramtin Agah, M.D.

Founder, Executive Chairman and Chief Medical Officer

Careers & Job Openings

No active job listings. Check back later.